

Rapid MRSA PCR on Respiratory Specimens from Ventilated Patients with Suspected Pneumonia: A Tool to Facilitate Antimicrobial Stewardship

Sergio E. Trevino^{a,c,&}, Morgan A. Pence^{b,&}, Jonas Marschall^{a,d}, Marin H. Kollef^c, Hilary M. Babcock^a and Carey-Ann D. Burnham^{b*}

^aDepartment of Medicine, Division of Infectious Diseases, ^bDepartment of Pathology & Immunology, Division of Laboratory and Genomic Medicine, ^cDepartment of Medicine, Division of Pulmonary and Critical Care, Washington University School of Medicine, St. Louis, MO, USA, ^dDepartment of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland

Running Title: MRSA PCR for suspected ventilator-associated pneumonia

&: These authors contributed equally to this work.

*Corresponding author:
Carey-Ann D. Burnham, PhD
Department of Pathology & Immunology
Division of Laboratory and Genomic Medicine
Washington University in St. Louis
660 S. Euclid Ave., Campus Box 8118
St. Louis, MO 63110
Telephone: +1 (314) 362-1547
E-mail: cburnham@wustl.edu

Abstract

Purpose: Methicillin-resistant *Staphylococcus aureus* (MRSA) is an important cause of pneumonia in ventilated patients. Our objective was to evaluate the GeneXpert MRSA/SA SSTI Assay (Xpert MRSA/SA) (Cepheid, Sunnyvale, CA) for use in lower respiratory tract (LRT) specimens for rapid MRSA detection and to determine the potentially saved antibiotic-days if a culture-based identification method was replaced by this assay.

Methods: Remnant LRT samples from ventilated patients submitted to the microbiology laboratory for routine culture were tested using conventional culture and Xpert MRSA/SA.

Results: One hundred (100) of 310 LRT specimens met inclusion criteria. Ten (10) samples were positive for MRSA by Xpert MRSA/SA, while 6 were positive by routine culture methods. Xpert MRSA/SA correctly identified 5/6 positive and 89/94 negative MRSA specimens for a sensitivity of 83.3%, specificity of 94.7%, positive predictive value of 45.6% and a negative predictive value of 98.9%. The assay also correctly detected 3/3 positive and 90/97 negative MSSA specimens for a sensitivity of 100%, specificity of 92.8%, positive predictive value of 30% and a negative predictive value of 100%. A total of 748 vancomycin and 305 linezolid antibiotic days were associated with the enrolled specimens. Vancomycin and linezolid utilization could decrease by 68.4% and 83%, respectively, if discontinued 1 day after negative PCR results.

Conclusions: The Xpert MRSA/SA SSTI rapid MRSA PCR assay performed well in respiratory samples from ventilated patients with suspected pneumonia and has the

potential to facilitate stewardship efforts such as reducing empiric vancomycin and linezolid therapy.

Keywords: MRSA, PCR, antimicrobial stewardship, ventilator-associated pneumonia, Xpert MRSA, *Staphylococcus aureus*

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is an important cause of ventilator-associated pneumonia (VAP) in the U.S. For patients with suspected VAP, treatment guidelines suggest empirical therapy to cover MRSA in addition to other potential pathogens [1]. Using conventional microbiologic methods, however, 48 h or more may elapse before MRSA can be reliably excluded from a lower respiratory tract (LRT) specimen, with tracheal aspirate (TA), bronchial washing (BW), or bronchoalveolar lavage (BAL) being the most frequently obtained specimen types. Thus, clinicians are faced with a long interval of diagnostic uncertainty, obligating prolonged use of broad-spectrum empiric antibiotic therapy.

The Xpert MRSA/SA SSTI (Cepheid, Sunnyvale, CA) assay is a polymerase chain reaction (PCR)-based assay, which is FDA cleared for detection of MRSA and methicillin-susceptible *S. aureus* (MSSA) in specimens collected from skin and soft tissue infections. The assay provides a result in approximately 1 h. To detect *S. aureus*, the assay relies on the detection of *spa*, the gene for staphylococcal protein A. To infer resistance to methicillin and identify the organism as MRSA, it must also detect the methicillin-resistance gene (*mecA*) and the junction between the staphylococcal cassette chromosome that harbors *mecA* (SCC*mec*) and the *S. aureus* chromosome.

The assay has been adapted for off-label use to detect MRSA in suspected ventilator-associated pneumonia [2,3] and osteoarticular infections [4].

Preliminary data in our institution demonstrate that approximately 20% of patients with cultures from LRT secretions obtained from Medical and Surgical Intensive Care Units (ICUs) were positive for *S. aureus*, with 9% determined to be methicillin-resistant. The Xpert MRSA/SA SSTI assay could be beneficial to reduce the interval of diagnostic uncertainty by identifying or ruling out MRSA in patients with suspected VAP and guiding antimicrobial therapy in a more timely fashion compared to conventional culture. The objectives of this study were two-fold: 1) to evaluate the analytical performance characteristics of the MRSA/SA SSTI assay for rapid detection of MRSA in LRT specimens and 2) to evaluate its potential role in antimicrobial stewardship efforts for managing suspected VAP, specifically concerning anti-MRSA agents.

Materials and Methods

Setting. Frozen and fresh LRT specimens collected at Barnes-Jewish Hospital, a 1,250 bed, tertiary care academic medical center, between 2012 and 2014 were included. The study was approved by the Washington University School of Medicine Institutional Review Board. All specimens included in the study were de-identified by an individual not otherwise associated with the study (i.e., the Honest Broker).

Standard-of-Care LRT Culture. BAL, BW and TA cultures were plated to 5% sheep's blood, chocolate and MacConkey agar (Remel, Lenexa, KS), using a 1 µl calibrated loop, and incubated at 35°C in an environment with 5% CO₂. Thresholds for workup of

BAL, BW and TA specimens were $\geq 10^3$ CFU/mL, $\geq 5 \times 10^3$ CFU/mL, and $\geq 10^5$ CFU/mL, respectively. Cultures were discarded if no growth was observed following 48 h of incubation. In *S. aureus*, methicillin resistance was confirmed using Kirby-Bauer disk diffusion in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines [5,6]. This standard-of-care LRT culture was used as the gold standard for comparison when calculating the analytical performance characteristics of the Xpert MRSA/SA.

Limit of detection (LOD) and reproducibility studies. LOD studies were performed using cultured isolates of *Staphylococcus epidermidis* (clinical isolate), *S. aureus* ATCC 29213 (MSSA), MRSA SCC*mec* type II, and MRSA SCC*mec* type IV (clinical isolates). Isolates were resuspended in 0.9% saline to a 0.5 McFarland and subsequently diluted to final concentrations of 10^5 , 10^4 , 10^3 and 10^2 CFU/mL. In addition, a negative saline control was analyzed. Subsequently, LOD studies were repeated in the matrix of pooled, *S. aureus*-negative, BAL fluid. Replicate testing, using 10^4 CFU/mL of the same group of organisms in BAL fluid, was performed over three consecutive days.

Retrospective samples. Study procedures were approved by the Washington University School of Medicine Institutional Review Board. Thirty (30) frozen banked LRT specimens (including 13 TAs and 17 BALs), obtained during routine diagnostic work-up prior to this study, were tested using the Xpert MRSA/SA SSTI assay, and the results were compared to the standard-of-care LRT culture result performed in the clinical microbiology laboratory. A flocked swab (Copan, Murrieta, CA) was placed into

the specimen and subsequently inserted into the Xpert elution buffer vial. Next, the swab was broken, and the vial was closed and vortexed for 10 sec. A sterile pipette was used to transfer the contents of the elution vial to the “S” chamber of the Xpert MRSA/SA cartridge, and the cartridge was loaded onto the GeneXpert Dx instrument. Testing was otherwise performed and results interpreted according to the manufacturer’s protocol.

Prospective samples. Specimens submitted to the microbiology laboratory for routine bacterial culture during the study period (November 2013 to March 2014) were screened by an Honest Broker for study eligibility in the prospective part of the study. The following 6 items were inclusion criteria: 1) subject ≥ 18 years of age, 2) patient admitted to the ICU, 3) patient on a ventilator at the time of sample collection, 4) ≥ 1 ml of remnant TA, BAL, or BW specimen available, 5) specimen tested by GeneXpert within 6 h of collection, and 6) presence of at least one of the following clinical criteria: a) active or recently discontinued use of broad-spectrum antibiotics (vancomycin, linezolid, cefepime or meropenem), b) temperature $>38.3^{\circ}\text{C}$ (within previous 72 h), c) white blood cell or leukocyte count $\geq 10,000/\mu\text{l}$ or $\leq 4,000/\mu\text{l}$ (within 72 h of specimen collection), d) purulent specimen (>25 polymorphonuclear cells/high power field) or e) recent intubation (within 72 h of specimen collection). Patients with a previous positive result from the Xpert MRSA/SA assay were excluded.

Specimens were screened for eligibility three times per day on weekdays by the Honest Broker. Three hundred ten (310) LRT specimens were screened, and 100 specimens met the study inclusion criteria and were tested using the Xpert MRSA/SA.

In addition to the standard-of-care culture, if a specimen was positive for MSSA or MRSA by the Xpert MRSA/SA, 100 µl and 500 µl aliquots were inoculated to blood agar (BD Diagnostics, Franklin Lakes, NJ), in addition to the standard-of-care culture, to attempt to isolate the organism. Isolates recovered using the larger aliquots were not included in sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) calculations.

Molecular Typing. SCCmec characterization was performed on *S. aureus* isolates using a previously described multiplex PCR assay that detects and differentiates SCCmec types I-V [7]. Strain typing of *S. aureus* isolates was performed by repetitive-sequence-based PCR (rep-PCR), using the Diversilab Bacterial Barcodes system (bioMérieux, Durham, NC) as previously described [8]. Isolates with a similarity index of $\geq 95\%$ were considered to represent the same strain.

Detection of high-level mupirocin resistance and chlorhexidine resistance. Phenotypic high-level mupirocin resistance was detected using a 200 µg mupirocin disk (Oxoid, Hampshire, United Kingdom) in accordance with CLSI guidelines [5]. In addition to phenotypic mupirocin resistance testing, a multiplex PCR for detection of *mupA* (mupirocin resistance) and *qacA/B* (chlorhexidine tolerance) was performed as previously described [8,9].

Antimicrobial stewardship applicability. Clinical data on subjects whose specimens met eligibility criteria were obtained from Washington University's medical informatics

clinical data repository, including microbiological culture results (for the LRT specimen tested in the study, in addition to any other positive culture results) as well as antimicrobials utilized. “Total antibiotic days” (all consecutive days that antibiotics were administered starting 48 hours prior to the study specimen collection date, until discontinued), were calculated for vancomycin and linezolid. Other antibiotics with activity against MRSA were not included. The number of antibiotic days that could have potentially been avoided was calculated using the “earliest date when antibiotics could be discontinued.” This was calculated as the calendar day after a negative MRSA PCR, given that no other clinical cultures were positive for MRSA. The potential reduction of antibiotic use (i.e., the number of antibiotic-days saved) was calculated by subtracting this number from the total antibiotic days.

Results

Limit of Detection Studies. The LOD in saline was 10^3 CFU/ml for MSSA and MRSA SCC*mec* type IV. For MRSA SCC*mec* type II, the LOD was 10^4 CFU/ml. In BAL fluid, the LOD was 10^3 CFU/ml for MSSA and MRSA SCC*mec* type II, while it was 10^4 CFU/ml for MRSA SCC*mec* type IV.

Retrospective validation samples. The Xpert MRSA/SA SSTI assay correctly detected MRSA in 9 of 9 specimens positive by routine culture and did not detect MRSA in 21 of 21 specimens negative by routine culture, resulting in a sensitivity of 100% (95% CI: 62.9-100%), specificity of 100% (95% CI: 80.8-100%), PPV of 100% (95% CI: 62.9-100%) and NPV of 100% (95% CI: 80.8-100%). In addition, MSSA was correctly

detected in 4 of 6 specimens positive by routine culture and was not detected in 24 of 24 specimens negative by routine culture, resulting in a sensitivity of 66.7% (95% CI: 24.1-94.0%), specificity of 100% (95% CI: 82.8-100%), PPV of 100% (95% CI: 39.6-100%) and NPV of 92.3% (95% CI: 73.4-98.7%). Four (4) isolates of MSSA and 7 isolates of MRSA were recovered from the subset of frozen specimens saved for molecular analysis.

Prospective samples. Of the 100 prospective specimens, which included BALs, TAs, and BWs, Xpert MRSA/SA detected MRSA in 5 of 6 specimens positive by standard-of-care culture resulting in a sensitivity of 83.3% (95% CI: 36.5-99.1%). The false negative was a BAL specimen. Xpert MRSA/SA detected MRSA in an additional 5 specimens, 4 BALs and 1 BW, where MRSA was not recovered by routine culture, resulting in a specificity of 94.7% (95% CI: 87.5-98.0%), a positive predictive value (PPV) of 50% (95% CI: 20.1-79.9%) and a negative predictive value (NPV) of 98.9% (95% CI: 93.1-99.9%) (Table 1). Of note, in higher volume cultures (500 μ L, was inoculated to 5% sheep's blood agar) MRSA was recovered in 3 of the 5 specimens that were negative by routine culture but positive by PCR. Mean cycle threshold (Ct) values were as follows: *spa* 26.41 (range 16.5–35.5), *mecA* 26.58 (range 17.6–32.5) and *scc* 27.94 (range 19.2–34.6) (Table 2).

The Xpert MRSA/SA assay detected MSSA in 3 of 3 specimens positive by routine culture, resulting in a sensitivity of 100% (95% CI: 31.0-100%). In addition, MSSA was detected in an additional 7 specimens, 5 BALs and 2 TAs, which were

negative by routine culture, for a specificity of 92.8% (95% CI: 85.2-96.8%). The PPV and NPV for MRSA were 30.0% (95% CI: 8.1-64.6%) and 100% (95% CI: 94.9-100%), respectively. In higher volume cultures (500 µl inoculated to 5% sheep's blood agar), MSSA was recovered in 2 additional specimens. The average *spa* cycle threshold was 29.32 (range 16.5 – 35.5) (Table 2). The *spa* cycle threshold for the 2 specimens in which MSSA was only recovered when plating 500 µl were 26.2 and 29.9.

Of the 100 prospective specimens, 36 were visibly bloody, and 13 specimens contained visible mucus; these specimens produced an Xpert MRSA/SA result on the first attempt with the exception of one viscous specimen, which resulted in a pressure error. The assay was repeated on the same specimen, and a valid result was obtained. Of the 51 non-bloody, non-viscous specimens, 3 specimens did not give a result on the first attempt. Two of the specimens gave an error message on the first run, while a third specimen gave an invalid result. The invalid specimen and one of specimens with an error message yielded a valid result upon repeating the assay. One specimen, that gave an error message on the first attempt, gave an invalid result on the second attempt. The specimen had to be diluted 1:10 with sterile saline before a valid result was obtained. Overall, the assay had to be repeated 4% of the time.

Characterization of isolates. A total of 15 MRSA and 9 MSSA isolates recovered from retrospective and prospective specimens were further characterized by SCC*mec* typing, high-level mupirocin resistance, chlorhexidine resistance, and molecular typing. Of the 15 MRSA isolates recovered, 12 isolates were SCC*mec* type II, and 3 isolates were SCC*mec* type IV. All 9 MSSA isolates were negative by SCC*mec* typing. Analysis of the

24 isolates by rep-PCR demonstrated heterogeneity of strains recovered. In total, 8 unique strain types were identified. The largest cluster contained 14 isolates, with the next two clusters containing 4 and 2 isolates. The second and third cluster were unrelated to the first cluster and to each other. Four unique isolates, unrelated to any other isolates in the study, were also identified.

Two isolates, both prospective MRSA isolates, were mupirocin resistant, by both phenotypic and genotypic (*mupA*) methods. None of the isolates tested contained the chlorhexidine tolerance gene, *qacA/B*.

Retrospective evaluation of the potential impact of Xpert MRSA/SA on Antimicrobial Stewardship. For 27 subjects in the study, MRSA was recovered in culture from a clinical specimen that was not evaluated as part of the study-- tracheal aspirate (24 from 15 subjects), bronchoalveolar lavage (8 from 7 subjects), blood (8 from 5 subjects), bronchial washing (6 from 6 subjects), sputum (1), joint fluid (1), abscess (1) and wound (1), with a subset of patients ($n = 6$) having more than one positive culture. Nares screening swabs for MRSA active surveillance were positive for 9 subjects.

Of the 100 subjects associated with the prospective specimen set, 96 received vancomycin and/or linezolid. The four subjects who did not receive these agents were negative for MRSA based on both Xpert MRSA/SA and culture.

Vancomycin was administered to 88 patients for a total of 748 total antibiotic days, and a mean duration of 8.5 days. Linezolid was administered to 28 patients for a total of 305 total antibiotic days and a mean duration of 10.9 days. If the anti-MRSA

agent had been discontinued 1 calendar day after a negative MRSA PCR result in patients without any additional culture or PCR results positive for MRSA (including surveillance swabs), total antibiotic days and mean duration would have decreased. Vancomycin total antibiotic days would have decreased by 68.4% (512 days) to a mean duration of 2.7 days; and linezolid would have decreased by 83% (253 days) to a mean duration of 1.9 days.

Cost analysis. An approximate cost estimate for a single Xpert MRSA/SA assay is \$60; thus for 100 patients, the test costs would have been \$6,000. This is an underestimate of true cost as it does not account for quality control testing, repeat testing, equipment acquisition, or labor. Based on the John's Hopkins Antibiotic Guide, average wholesale prices for the evaluated antimicrobials are estimated to be approximately \$15.56 per day (based on a dose of 1 g b.i.d.) for vancomycin and \$240.22 per day (based on a dose of 600 mg b.i.d.) for linezolid [10]. This is also an underestimate as it does not take into account drug administration costs or expenses for therapeutic drug monitoring and other laboratory testing, such as laboratory testing to monitor renal function in patients receiving vancomycin therapy. It also does not take into account the costs associated with complications due to these antibiotics, particularly vancomycin and renal injury. If vancomycin usage was reduced by 512 days, it would result in savings of \$7,966.72 in drug cost, and if linezolid usage was decreased by 253 days, it would result in savings of \$60,775.66 in drug cost. Based on these estimates, the total potential antibiotic savings were \$62,742.38. Thus, an estimate of potential cost savings would be \$627.42 per patient.

Discussion

Antimicrobial resistance is an increasing threat in the U.S. and worldwide. The CDC has recently listed MRSA as one of the current antibiotic threats in the U.S. and has assigned it a threat level of “Serious” [11]. One core approach to address antimicrobial resistance is to reduce unnecessary antibiotic use, and in order to do so, it is imperative to reduce the window of diagnostic uncertainty, thus shortening the duration of empiric antibiotics.

The Infectious Diseases Society of America (IDSA) recently published a public policy document declaring that in order for tests to have a positive impact on patient care, new tests need to provide information about the causative organism, including antimicrobial susceptibility/resistance information, if possible, and must have rapid results, ideally within 1 hour [12,13]. Even with the development of rapid assays, however, the positive impact on patient care can only be achieved if physicians act quickly upon the results and start adequate or stop inadequate antibiotics. Such tests have been scrutinized for the detection of bloodborne pathogens, in a number of studies, often with a positive impact in antimicrobial stewardship efforts [14-16]. There are currently no commercial pathogen-specific assays available for evaluating respiratory specimens for hospital-acquired pneumonia (HAP) or VAP, although the MRSA/SA SSTI assay has been evaluated off-label in this and two prior studies.

One specimen that was positive for MRSA by routine culture was negative by the MRSA/SA SSTI assay. A limitation of the Xpert assay compared to culture is that the assay may not detect emerging *SCCmec* variants, and it is possible that the isolate may

have been an SCC*mec* variant [17]. Laboratories considering implementing the assay should consider local epidemiology before relying on PCR to exclude the presence of *S. aureus* in respiratory tract specimens.

Seven specimens (2 MRSA, 5 MSSA) were positive by the MRSA/SA SSTI assay but negative by culture. All 7 specimens had *spa* PCR cycle thresholds greater than 30 when tested by the MRSA/SA SSTI assay, suggesting that the organism burden in these specimens was low. Alternatively, the PCR assay may have been detecting remnant DNA from dead organisms. Three additional MRSA PCR positive specimens also had *spa* cycle thresholds greater than 30, but those 3 were recovered in culture. However, in those 3 cases, MRSA was not recovered in routine culture and was only recovered when a larger volume (500 µl) was evaluated. The organism burden in these specimens may thus represent colonization rather than infection, or it may represent non-viable organisms after exposure to antimicrobials, such as linezolid or vancomycin. Laboratories considering such testing may wish to modify the Ct cutoff value for reporting positive PCR results from respiratory specimens.

Two previous studies have examined the performance of the MRSA/SA SSTI assay on LRT specimens. In a validation study, the sensitivity, specificity, and positive and negative predictive values were 99%, 72.2%, 90.7% and 96.3%, respectively, when compared with quantitative cultures for detecting MRSA in LRT samples [3]. Leone *et al.* utilized the assay to evaluate the presence of MSSA or MRSA in LRT samples of patients with suspected VAP, and reported negative predictive values of 99.7% and 99.8%, respectively. In contrast to the evaluation described herein (where MRSA prevalence was 8%), a limitation of the Leone study is that the reported MRSA

prevalence was <2%. Neither study estimated the impact of the assay on antimicrobial stewardship efforts or antimicrobial cost avoidance. Other studies have evaluated automated microscopy of mini-bronchoalveolar lavage specimens [18], nares MRSA screening [19] and the Gram stain of a respiratory specimen [20] for the likelihood and diagnosis of VAP.

The strengths of this study include that it was conducted in a high-prevalence, high-acuity setting and that it included a calculation of total antibiotic days, potential antibiotic days saved, and an estimated cost savings analysis. In addition, the strain typing and characterization data demonstrate that multiple *S. aureus* strain types were recovered from the patients in this study. The variety of strain types detected verifies that off-label use of the assay is capable of detecting multiple *S. aureus* strain types, and it also proves that the study, although conducted at a single center, did not simply repeatedly test the same clone.

The limitations of this study include the fact that the assay results were not reported for use into routine clinical care, and all the clinical data were obtained retrospectively from the medical record. Thus, the cost analysis presented is an estimate based on the assumption that the assay results would have impacted antimicrobial therapy. In addition, the cost analysis does not take into consideration patients without clinical improvement after 48-72 h, where discontinuation of vancomycin or linezolid would be unlikely to occur. However, these data suggest that incorporation of this test into the management of ICU patients suspected to have VAP has the potential to provide cost savings to hospitals.

There are currently no commercially available assays for rapid detection of MRSA/MSSA in LRT specimens, and thus, off-label use of the Xpert MRSA/SA SSTI assay is a promising alternative for the microbiological diagnosis of VAP. Herein, we demonstrate the sensitivity and specificity of this approach, and suggest that rapid detection of MRSA in LRT specimens using this assay could be a tool to support antimicrobial stewardship efforts in patients with suspected ventilator-associated pneumonia. Prospective studies incorporating this approach into routine clinical use are needed to confirm these findings.

Compliance with Ethical Standards

Funding: This study was funded by a Barnes-Jewish Hospital Patient Safety and Quality Fellowship (to J.M.) and a BIRCWH grant (5K12HD001459-13; J.M.). The funders had no role in study design, data collection and interpretation or the decision to submit the work for publication.

Conflict of Interest: C.A.B. has received research support from Cepheid. J.M. has served on an advisory board for Astellas Switzerland.

Ethical approval: The study was approved by the Washington University Institutional Review Board.

Informed consent: Informed consent was not required for this study.

Acknowledgments: The authors thank Meghan Wallace for her assistance as Honest Broker.

345

346 **References**

347 1. AmericanThoracicSocietyandInfectiousDiseasesSocietyofAmerica. (2005) Guidelines for the
348 management of adults with hospital-acquired, ventilator-associated, and healthcare-associated
349 pneumonia. American journal of respiratory and critical care medicine 171 (4):388-416.
350 doi:10.1164/rccm.200405-644ST

351 2. Leone M, Malavieille F, Papazian L, Meyssignac B, Cassir N, Textoris J, Antonini F, La Scola
352 B, Martin C, Allaouchiche B, Hraiech S, AzuRea N (2013) Routine use of *Staphylococcus*
353 aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia. Crit Care
354 17 (4):R170. doi:10.1186/cc12849

355 3. Cercenado E, Marin M, Burillo A, Martin-Rabadan P, Rivera M, Bouza E (2012) Rapid
356 detection of *Staphylococcus aureus* in lower respiratory tract secretions from patients with
357 suspected ventilator-associated pneumonia: evaluation of the Cepheid Xpert MRSA/SA SSTI
358 assay. Journal of clinical microbiology 50 (12):4095-4097. doi:10.1128/jcm.02409-12

359 4. Dubouix-Bourandy A, de Ladoucette A, Pietri V, Mehdi N, Benzaquen D, Guinand R,
360 Gandois JM (2011) Direct detection of *Staphylococcus* osteoarticular infections by use of Xpert
361 MRSA/SA SSTI real-time PCR. Journal of clinical microbiology 49 (12):4225-4230.
362 doi:10.1128/jcm.00334-11

- 363 5. CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth
364 Informational Supplement. CLSI document M100-S24. Wayne, PA: Clinical and Laboratory
365 Standards Institute; 2014.
- 366 6. CLSI Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved
367 Standard—Eleventh Edition. CLSI document M02-A11. Wayne, PA: Clinical and Laboratory
368 Standards Institute; 2012.
- 369 7. Boye K, Bartels MD, Andersen IS, Moller JA, Westh H (2007) A new multiplex PCR for easy
370 screening of methicillin-resistant *Staphylococcus aureus* SCCmec types I-V. Clinical
371 microbiology and infection : the official publication of the European Society of Clinical
372 Microbiology and Infectious Diseases 13 (7):725-727. doi:10.1111/j.1469-0691.2007.01720.x
- 373 8. Fritz SA, Hogan PG, Camins BC, Ainsworth AJ, Patrick C, Martin MS, Krauss MJ, Rodriguez
374 M, Burnham CA (2013) Mupirocin and chlorhexidine resistance in *Staphylococcus aureus* in
375 patients with community-onset skin and soft tissue infections. Antimicrobial agents and
376 chemotherapy 57 (1):559-568. doi:10.1128/aac.01633-12
- 377 9. Hogue JS, Buttke P, Braun LE, Fairchok MP (2010) Mupirocin resistance related to increasing
378 mupirocin use in clinical isolates of methicillin-resistant *Staphylococcus aureus* in a pediatric
379 population. Journal of clinical microbiology 48 (7):2599-2600. doi:10.1128/jcm.02118-09

- 380 10. Bartlett JG, ed. (2016) The Johns Hopkins POC-IT ABX Guide.
381 http://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540602/all/**About
382 [**](#). Accessed March 20, 2016
- 383 11. CDC. (2013) Centers for Disease Control. Antibiotic Resistance Threats in the United States,
384 2013. <http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf>. Accessed March 20, 2016
- 385 12. Caliendo AM, Gilbert DN, Ginocchio CC, Hanson KE, May L, Quinn TC, Tenover FC,
386 Alland D, Blaschke AJ, Bonomo RA, Carroll KC, Ferraro MJ, Hirschhorn LR, Joseph WP,
387 Karchmer T, MacIntyre AT, Reller LB, Jackson AF, Infectious Diseases Society of A (2013)
388 Better tests, better care: improved diagnostics for infectious diseases. Clin Infect Dis 57 Suppl
389 3:S139-170. doi:10.1093/cid/cit578
- 390 13. Bauer KA, Perez KK, Forrest GN, Goff DA (2014) Review of rapid diagnostic tests used by
391 antimicrobial stewardship programs. Clinical infectious diseases : an official publication of the
392 Infectious Diseases Society of America 59 Suppl 3:S134-145. doi:10.1093/cid/ciu547
- 393 14. Banerjee R, Teng CB, Cunningham SA, Ihde SM, Steckelberg JM, Moriarty JP, Shah ND,
394 Mandrekar JN, Patel R (2015) Randomized Trial of Rapid Multiplex Polymerase Chain
395 Reaction-Based Blood Culture Identification and Susceptibility Testing. Clinical infectious
396 diseases : an official publication of the Infectious Diseases Society of America 61 (7):1071-1080.
397 doi:10.1093/cid/civ447

- 398 15. Parta M, Goebel M, Matloobi M, Stager C, Musher DM (2009) Identification of methicillin-
399 resistant or methicillin-susceptible *Staphylococcus aureus* in blood cultures and wound swabs by
400 GeneXpert. *Journal of clinical microbiology* 47 (5):1609-1610. doi:10.1128/JCM.00351-09
- 401 16. Spencer DH, Sellenriek P, Burnham CA (2011) Validation and implementation of the
402 GeneXpert MRSA/SA blood culture assay in a pediatric setting. *American journal of clinical*
403 *pathology* 136 (5):690-694. doi:10.1309/AJCP07UGYOKBVVNC
- 404 17. Laurent C, Bogaerts P, Schoevaerds D, Denis O, Deplano A, Swine C, Struelens MJ,
405 Glupczynski Y (2010) Evaluation of the Xpert MRSA assay for rapid detection of methicillin-
406 resistant *Staphylococcus aureus* from nares swabs of geriatric hospitalized patients and failure to
407 detect a specific SCCmec type IV variant. *Eur J Clin Microbiol Infect Dis* 29 (8):995-1002.
408 doi:10.1007/s10096-010-0958-3
- 409 18. Douglas IS, Price CS, Overdier KH, Wolken RF, Metzger SW, Hance KR, Howson DC
410 (2015) Rapid automated microscopy for microbiological surveillance of ventilator-associated
411 pneumonia. *American journal of respiratory and critical care medicine* 191 (5):566-573.
412 doi:10.1164/rccm.201408-1468OC
- 413 19. Langsjoen J, Brady C, Obenauf E, Kellie S (2014) Nasal screening is useful in excluding
414 methicillin-resistant *Staphylococcus aureus* in ventilator-associated pneumonia. *American*
415 *journal of infection control* 42 (9):1014-1015. doi:10.1016/j.ajic.2014.05.026

416 20. O'Horo JC, Thompson D, Safdar N (2012) Is the gram stain useful in the microbiologic
417 diagnosis of VAP? A meta-analysis. *Clinical infectious diseases* : an official publication of the
418 Infectious Diseases Society of America 55 (4):551-561. doi:10.1093/cid/cis512

419

420 Table 1. Detection of MRSA and MSSA in Prospective Samples (n=100)

MRSA	<u>Culture Positive</u>	<u>Culture Negative</u>
Xpert Positive	5	5
Xpert Negative	1	89
MSSA	<u>Culture Positive</u>	<u>Culture Negative</u>
Xpert Positive	3	7
Xpert Negative	0	90

421 Table 2. Xpert MRSA/SA Results for Positive Prospective Lower Respiratory Tract Specimens

Specimen Type (BAL, BW or TA)	Culture Result	Xpert MRSA/SA Result	<i>spa</i> Ct Value	<i>mecA</i> Ct Value	<i>scc</i> Ct Value	SCC <i>mec</i> Type*	<i>mupA</i> (PCR/disk diffusion testing)
TA	Positive	MSSA	24.2	29.8	0	None	Negative/S
BAL	Negative	MSSA	35.3	0	0	N/A	N/A
BAL	Positive	MRSA	30.3	30.3	31.6	II	Negative/S
TA	Positive	MSSA	26.2	33.3	0	None	Negative/S
BAL	Negative	MSSA	30.6	0	0	N/A	N/A
BAL	Negative	MRSA	32.4	31.1	33.4	N/A	N/A
BAL	Positive	MRSA	20.3	21.0	22.1	II	Negative/S
TA	Positive	MSSA	16.5	21.6	0	None	Negative/S
TA	Positive	MSSA	29.9	0	0	None	Negative/S
BAL	Positive	MRSA	32.6	28.4	29.1	II	Negative/S
BAL	Positive	MSSA	27.0	0	0	None	Negative/S
BAL	Negative	MRSA	32.5	32.9	34.6	N/A	N/A
TA	Positive	MRSA	21.1	21.2	22.5	II	Positive/S
BAL	Negative	MSSA	34.6	0	0	N/A	N/A
TA	Positive	MRSA	17.6	17.8	19.2	IV	Negative/S
BAL	Positive	MRSA	27.0	27.3	28.4	II	Positive/S
BAL	Negative	MSSA	35.5	0	0	N/A	N/A
BAL	Positive	MRSA	23.1	23.3	24.5	IV	Negative/S
BAL	Negative	MSSA	33.4	0	0	N/A	N/A
BW	Positive	MRSA	31.4	31.8	33.1	II	Negative/S

438 Abbreviations: BAL, bronchoalveolar lavage; BW, bronchial washing; TA, tracheal aspirate; Ct, cycle threshold

439 *N/A indicates an isolate was not recovered, so testing was not performed. None indicates the absence of a detectable SCC*mec* type.